Inovio Pharmaceuticals (INO) News Today $1.58 -0.01 (-0.63%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period INOVIO to Present at Upcoming Scientific ConferencesApril 9 at 8:05 AM | prnewswire.comINOVIO to Present at Upcoming Scientific ConferencesApril 9 at 8:05 AM | prnewswire.comInovio Pharmaceuticals (NASDAQ:INO) Upgraded at StockNews.comStockNews.com upgraded shares of Inovio Pharmaceuticals to a "sell" rating in a report on Friday.March 22, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for INO EarningsInovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - HC Wainwright raised their Q1 2025 EPS estimates for Inovio Pharmaceuticals in a report issued on Wednesday, March 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share ofMarch 22, 2025 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $5.00 at Royal Bank of CanadaRoyal Bank of Canada lowered their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating for the company in a research report on Wednesday.March 20, 2025 | marketbeat.comHC Wainwright Reiterates Neutral Rating for Inovio Pharmaceuticals (NASDAQ:INO)HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday.March 20, 2025 | marketbeat.comRBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)March 19, 2025 | markets.businessinsider.comInovio price target lowered to $5 from $6 at RBC CapitalMarch 19, 2025 | markets.businessinsider.comInovio reports Q4 EPS (65c), consensus (83c)March 19, 2025 | markets.businessinsider.comInovio price target lowered to $12 from $18 at Citizens JMPMarch 19, 2025 | markets.businessinsider.comInovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issuesMarch 19, 2025 | msn.comInovio Pharmaceuticals (NASDAQ:INO) Announces Quarterly Earnings Results, Beats Estimates By $0.23 EPSInovio Pharmaceuticals (NASDAQ:INO - Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.23.March 19, 2025 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPSInovio Pharmaceuticals (NASDAQ:INO - Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.23.March 19, 2025 | marketbeat.comInovio Pharmaceuticals (INO) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comInovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | seekingalpha.comINOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational HighlightsMarch 18, 2025 | prnewswire.comInovio reports ‘promising’ interim results from DMAbs trialMarch 13, 2025 | markets.businessinsider.comINOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19March 13, 2025 | prnewswire.comINOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025March 12, 2025 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have givenMarch 1, 2025 | marketbeat.comInovio Pharmaceuticals (INO) to Release Quarterly Earnings on WednesdayInovio Pharmaceuticals (NASDAQ:INO) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports.February 26, 2025 | marketbeat.comAN2 Therapeutics, Inc. (ANTX) Gets a Buy from JMP SecuritiesFebruary 20, 2025 | markets.businessinsider.comINO-3107 shows promise in reducing surgeries for RRP patientsFebruary 12, 2025 | msn.comInovio announces peer-reviewed data from phase 1/2 clinical trial with INO-307February 12, 2025 | markets.businessinsider.comInovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)February 12, 2025 | seekingalpha.comClinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature CommunicationsFebruary 12, 2025 | prnewswire.comImmune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) ConferenceFebruary 10, 2025 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.40 Average Price Target from BrokeragesShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and three have issued a buyFebruary 7, 2025 | marketbeat.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has earned an average rating of "Moderate Buy" from the five analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the compFebruary 4, 2025 | marketbeat.comINOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 29, 2025 | prnewswire.comInovio price target lowered to $3 from $5 at H.C. WainwrightJanuary 13, 2025 | markets.businessinsider.comHC Wainwright Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $3.00HC Wainwright dropped their price target on Inovio Pharmaceuticals from $5.00 to $3.00 and set a "neutral" rating on the stock in a report on Monday.January 13, 2025 | marketbeat.comInovio CEO sees 2025 to be ‘transformational year’January 10, 2025 | markets.businessinsider.comInovio Pharmaceuticals’ Strategic Position Bolstered by INO-3107 Breakthrough and Fast Track DesignationsJanuary 10, 2025 | markets.businessinsider.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has received a consensus rating of "Moderate Buy" from the four brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and two have issued a buy rating on the company. TJanuary 10, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Inovio Pharmaceuticals (NASDAQ:INO)JMP Securities reissued a "market outperform" rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday.January 10, 2025 | marketbeat.comINOVIO Highlights Anticipated 2025 Milestones and 2024 Key AccomplishmentsJanuary 9, 2025 | finance.yahoo.comINOVIO Highlights Anticipated 2025 Milestones and 2024 Key AccomplishmentsJanuary 9, 2025 | prnewswire.comInvestors Look to End Week on Strong Note as US Futures Rise in Friday's PremarketDecember 13, 2024 | msn.comInovio Pharmaceuticals Prices $30 Mln Public Offering With WarrantsDecember 13, 2024 | markets.businessinsider.comInovio announces common stock and warrants offering, no amount givenDecember 13, 2024 | markets.businessinsider.comINOVIO Announces Pricing of $30 Million Public OfferingDecember 13, 2024 | prnewswire.comInovio Down 20% After Hours on Planned Stock and Warrant SaleDecember 12, 2024 | marketwatch.comINOVIO Announces Proposed Public OfferingDecember 12, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to thDecember 12, 2024 | marketbeat.comINOVIO Reports Data From Retrospective Trial Evaluating INO-3107 - Quick FactsDecember 3, 2024 | markets.businessinsider.comInovio’s INO-3107 shows efficacy in Phase 1/2 RRP trialDecember 3, 2024 | markets.businessinsider.comNew Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 TrialDecember 3, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Up 7.1% in NovemberInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 3,750,000 shares, a growth of 7.1% from the October 31st total of 3,500,000 shares. Based on an average daily volume of 336,300 shares, the short-interest ratio is currently 11.2 days. Approximately 14.5% of the company's stock are short sold.December 3, 2024 | marketbeat.comINOVIO Reports Inducement Grant Under Inducement PlanNovember 29, 2024 | prnewswire.com Remove Ads Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address INO Media Mentions By Week INO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INO News Sentiment▼0.720.92▲Average Medical News Sentiment INO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INO Articles This Week▼33▲INO Articles Average Week Remove Ads Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nevro News AVITA Medical News Nyxoah News Inogen News Electromed News Alpha Tau Medical News Pro-Dex News LENSAR News BrainsWay News Lakeland Industries News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INO) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
